At a glance
ClinicalIndex Comparison RecordPhase 2Completed
Drug / intervention
Collection of treatment-stratefying prognostic factorsprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GRAALL 2003 Trial (ALL 15-59 Years). Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial
In Brief
A Phase 2 clinical trial evaluating Collection of treatment-stratefying prognostic factors for Acute Lymphoblastic Leukemia. Completed, across 1 site.
Detailed Summary
Several prognostic predictors, including baseline ALL features and response to initial therapy, have been described in adult ALL raising the issue of whether these predictors might be redundant and which must be considered for treatment stratification. In the GRAALL-2003 prospective Phase 2 study, we aim to hierarchize the following high-risk factors in Ph-negative ALL patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia
CountriesFrance
CollaboratorsMinistry of Health, France
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
First PostedSep 2005
Primary CompletionOct 2008
Study CompletionDec 2008
TodayJul 2026
First PostedSep 22, 2005
Enrollment StartNov 1, 2003
Primary CompletionOct 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 20.8 years ago
Interventions
Collection of treatment-stratefying prognostic factorsprocedure